EGFR and non-small cell lung carcinoma: Importantly, in the current time when treatment options for front line EGFR mutant NSCLC may soon range between EGFR TKI monotherapy, TKI-chemotherapy combination, or lazertinib-amivantamab, lack of ctDNA clearance may assist in patient selection for those in whom treatment intensification above TKI monotherapy may be most useful, and inversely, those in whom treatment deintensification to TKI monotherapy may suit best.